Skip to main content
Premium Trial:

Request an Annual Quote

Aventis Pharm and Qiagen Sign Deal for Non-PCR Microarray Platform

NEW YORK, June 28 - Qiagen and Aventis have signed a technology access agreement for Qiagen's new ZeptoGene Workstation microarray platform, Qiagen said Thursday. 

Under the agreement, Aventis will acquire limited access to the platform, which can be used for both nucleic acid and protein analysis.  

Qiagen developed the microarray platform in a multi-year collaboration with Swiss company Zeptosens, a spinoff of Novartis. The platform employs Zeptosens' Planar Wave Guide technology, a method for selectively detecting molecules bound to the surface of the microarray without the use of PCR, as well as Qiagen's nucleic acid separation purification and handling technologies. 

"The PWG chip technology has the potential to give us more precise information about the expression pattern of genes that are expressed at very low levels and only slightly differentially expressed genes," Jutta Reinhard-Rupp, Aventis Pharma's head of functional  genomics, said in a statement. "This advantage can significantly accelerate our target validation process and will support our understanding of diseases and their mechanisms."

The ZeptoGene platform offers more sensitive detection of expression than conventional microarrays, Qiagen said, as well as the capability to perform more in-depth analysis of data obtained from conventional microarrays using the ZeptoGene platform. It can also analyze the interrelationships between protein and gene samples in a single platform, Qiagen said. 

Qiagen has an undisclosed equity stake in Basel, Switzerland-based Zeptosens. Zeptosens and Venlo, Netherlands-based Qiagen formed an alliance in January 2000 to commercialize DNA microarray and other biochip technology. In addition to a substantial equity contribution, Qiagen also agreed to finance certain R&D activities and provide sales and marketing support, according to Zeptosens' website.  

Peer Schatz, Qiagen's chief financial officer, said that a deal similar to the Aventis arrangement would typically have a value between $42,000 and $86,000.
The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.